The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 09, 2021
Filed:
Jan. 31, 2020
Florida State University Research Foundation, Inc., Tallahassee, FL (US);
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
The Johns Hopkins University, Baltimore, MD (US);
Hengli Tang, Tallahassee, FL (US);
Emily M. Lee, Tallahassee, FL (US);
Yichen Cheng, Tallahassee, FL (US);
Yi Zhou, Tallahassee, FL (US);
Wei Zheng, Rockville, MD (US);
Ruili Huang, Rockville, MD (US);
Miao Xu, Rockville, MD (US);
Wenwei Huang, Rockville, MD (US);
Menghang Xia, Rockville, MD (US);
Hongjun Song, Baltimore, MD (US);
Guo-Li Ming, Baltimore, MD (US);
Zhexing Wen, Atlanta, GA (US);
FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., Tallahassee, FL (US);
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US);
THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US);
Abstract
The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.